Key result
The coexistence of dyslipidemia and hypertension, termed 'lipitension', has a multiplicative adverse impact on cardiovascular risk, highlighting the need for simultaneous aggressive management.
The co-existence of dyslipidemia and hypertension, termed 'LIPITENSION', requires easy identification and aggressive management to prevent future cardiovascular events.
May support concurrent hypertension-dyslipidemia management; leaves open randomized confirmation of multiplicative risk reduction.
The burden of cardiovascular disease (CVD) is increasing worldwide. The increase in the burden is a major concern in developing countries like India. It is well-established that hypertension and dyslipidemia are the two major contributing risk factors for CVD. Various epidemiological studies have shown the prevalence of the co-existence of hypertension and dyslipidemia, in the range of 15 to 31%. The co-existence of the two risk factors has more than an additive adverse impact on the vascular endothelium, which results in enhanced atherosclerosis, leading to CVD. This review emphasizes on the 'co-existence and interplay of dyslipidemia and hypertension'. The authors have termed the co-existence as, 'LIPITENSION'. The term LIPITENSION may help clinicians in easy identification and aggressive management of the two conditions together, ultimately preventing future cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Gulati et al. (2012) conducted a review in Dyslipidemia and hypertension (Lipitension). The coexistence of dyslipidemia and hypertension, termed 'lipitension', has a multiplicative adverse impact on cardiovascular risk, highlighting the need for simultaneous aggressive management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: